**CONTENTS**

**IN THIS ISSUE**
Highlighted research articles .................. 961

**NEWS IN BRIEF**
Important news stories affecting the community .................. 964

**NEWS IN DEPTH**
Q&A: George Sledge on Trends in Clinical Trials .......... 967
Emphasizing the Provocative .................. 968

**RESEARCH WATCH**
Selected highlights of recent articles of exceptional significance from the cancer literature .................. 969

**ONLINE**
For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

**VIEWS**
In The Spotlight
The Potential of Circulating Tumor Cells as a Liquid Biopsy to Guide Therapy in Prostate Cancer .................. 974
K. Pantel and C. Alix-Panabières
Commentary on Miyamoto et al., p. 995

**RESEARCH ARTICLES**
The Promise of Combining Inhibition of PI3K and PARP as Cancer Therapy ............... 982
F.L. Rehman, C.J. Lord, and A. Ashworth
Commentary on Ibrahim et al., p. 1036, and Juvekar et al., p. 1048

**REVIEW**
Measuring Oncogenic Signaling Pathways in Cancer with PET: An Emerging Paradigm from Studies in Castration-Resistant Prostate Cancer .................. 985
M.J. Evans

**RESEARCH BRIEF**
Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer .................. 995
Précis: Automated immunofluorescence imaging of circulating tumor cells can noninvasively detect androgen receptor activity in patients with metastatic prostate cancer.

**IN THIS ISSUE**
Highlighted research articles .................. 961

**NEWS IN BRIEF**
Important news stories affecting the community .................. 964

**NEWS IN DEPTH**
Q&A: George Sledge on Trends in Clinical Trials .......... 967
Emphasizing the Provocative .................. 968

**RESEARCH WATCH**
Selected highlights of recent articles of exceptional significance from the cancer literature .................. 969

**ONLINE**
For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

**VIEWS**
In The Spotlight
The Potential of Circulating Tumor Cells as a Liquid Biopsy to Guide Therapy in Prostate Cancer .................. 974
K. Pantel and C. Alix-Panabières
Commentary on Miyamoto et al., p. 995

**RESEARCH ARTICLES**
The Promise of Combining Inhibition of PI3K and PARP as Cancer Therapy ............... 982
F.L. Rehman, C.J. Lord, and A. Ashworth
Commentary on Ibrahim et al., p. 1036, and Juvekar et al., p. 1048

**REVIEW**
Measuring Oncogenic Signaling Pathways in Cancer with PET: An Emerging Paradigm from Studies in Castration-Resistant Prostate Cancer .................. 985
M.J. Evans

**RESEARCH BRIEF**
Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer .................. 995
Précis: Automated immunofluorescence imaging of circulating tumor cells can noninvasively detect androgen receptor activity in patients with metastatic prostate cancer.

**IN THIS ISSUE**
Highlighted research articles .................. 961

**NEWS IN BRIEF**
Important news stories affecting the community .................. 964

**NEWS IN DEPTH**
Q&A: George Sledge on Trends in Clinical Trials .......... 967
Emphasizing the Provocative .................. 968

**RESEARCH WATCH**
Selected highlights of recent articles of exceptional significance from the cancer literature .................. 969

**ONLINE**
For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

**VIEWS**
In The Spotlight
The Potential of Circulating Tumor Cells as a Liquid Biopsy to Guide Therapy in Prostate Cancer .................. 974
K. Pantel and C. Alix-Panabières
Commentary on Miyamoto et al., p. 995

**RESEARCH ARTICLES**
The Promise of Combining Inhibition of PI3K and PARP as Cancer Therapy ............... 982
F.L. Rehman, C.J. Lord, and A. Ashworth
Commentary on Ibrahim et al., p. 1036, and Juvekar et al., p. 1048

**REVIEW**
Measuring Oncogenic Signaling Pathways in Cancer with PET: An Emerging Paradigm from Studies in Castration-Resistant Prostate Cancer .................. 985
M.J. Evans

**RESEARCH BRIEF**
Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer .................. 995
Précis: Automated immunofluorescence imaging of circulating tumor cells can noninvasively detect androgen receptor activity in patients with metastatic prostate cancer.

**IN THIS ISSUE**
Highlighted research articles .................. 961

**NEWS IN BRIEF**
Important news stories affecting the community .................. 964

**NEWS IN DEPTH**
Q&A: George Sledge on Trends in Clinical Trials .......... 967
Emphasizing the Provocative .................. 968

**RESEARCH WATCH**
Selected highlights of recent articles of exceptional significance from the cancer literature .................. 969

**ONLINE**
For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

**VIEWS**
In The Spotlight
The Potential of Circulating Tumor Cells as a Liquid Biopsy to Guide Therapy in Prostate Cancer .................. 974
K. Pantel and C. Alix-Panabières
Commentary on Miyamoto et al., p. 995

**RESEARCH ARTICLES**
The Promise of Combining Inhibition of PI3K and PARP as Cancer Therapy ............... 982
F.L. Rehman, C.J. Lord, and A. Ashworth
Commentary on Ibrahim et al., p. 1036, and Juvekar et al., p. 1048

**REVIEW**
Measuring Oncogenic Signaling Pathways in Cancer with PET: An Emerging Paradigm from Studies in Castration-Resistant Prostate Cancer .................. 985
M.J. Evans

**RESEARCH BRIEF**
Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer .................. 995
Précis: Automated immunofluorescence imaging of circulating tumor cells can noninvasively detect androgen receptor activity in patients with metastatic prostate cancer.
Genome-wide DNA Methylation Events in TMPRSS2-ERG Fusion-Negative Prostate Cancers Implicate an EZH2-Dependent Mechanism with miR-26a Hypermethylation .......... 1024

Précis: EZH2 overexpression is caused by miR-26a hypermethylation in prostate cancers lacking the TMPRSS2-ERG gene fusion, which have distinct DNA methylation profiles.

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition .......... 1036

Précis: PI3K suppression represses BRCA1/2 expression and increases the sensitivity of BRCA-wild-type breast cancer cells to PARP inhibitors via ERK activation.

Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer .......... 1048

Précis: PI3K inhibition synergizes with PARP inhibitors in vivo to decrease the growth of BRCA1-mutant breast tumors, revealing a role for PI3K in the DNA damage response.